TAcs 40 mg

DRUG2 trials

Sponsors

Pacira Pharmaceuticals, Inc

Conditions

Bilateral Knee OsteoarthritisOsteoarthritis of the HipOsteoarthritis of the Shoulder

Phase 2

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

CompletedNCT03378076

Pacira Pharmaceuticals, IncBilateral Knee Osteoarthritis

Start: 2017-12-06End: 2018-03-14Updated: 2024-01-24

Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

CompletedNCT03382262

Pacira Pharmaceuticals, IncOsteoarthritis of the Hip, Osteoarthritis of the Shoulder

Start: 2017-12-18End: 2018-10-09Updated: 2024-01-24

Related Papers

A Randomized, Open-Label, Single-Dose Study to Assess Safety and Systemic Exposure of Triamcinolone Acetonide Extended-Release in Patients With Hip Osteoarthritis

Rheumatology and Therapy2022-03-085 citations

Safety and Systemic Exposure of Triamcinolone Acetonide Following Ultrasound-Guided Intra-Articular Injection of Triamcinolone Extended-Release or Standard Triamcinolone Acetonide in Patients with Shoulder Osteoarthritis: An Open-Label, Randomized Study.

2021-08-047 citations

A randomized, phase IIa study to assess the systemic exposure of triamcinolone acetonide following injection of extended-release triamcinolone acetonide or traditional triamcinolone acetonide into both knees of patients with bilateral knee osteoarthritis

Therapeutic Advances in Musculoskeletal Disease2019-01-019 citations